In a phase II study (UMIN000005714) using nivolumab (anti-PD-1), 10% of patients with platinum-resistant ovarian cancer demonstrated durable complete response, with a partial response in 15% of those enrolled [32]. This evidence concerns the gene PDCD1 and ovarian cancer.